Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $58.99 | $5.90/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| TB10GA-02 | — | 99.9% | Kovera Labs | Endotoxin, Sterility, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. TB-500 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Glacier Aminos sell TB-500?
Yes — Glacier Aminos currently lists TB-500 in 1 variant starting at $58.99 ($5.90/mg).
Is Glacier Aminos's TB-500 third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Glacier Aminos's TB-500, with the most recent showing 99.9% purity. Glacier Aminos holds an overall trust grade of A (96/100) across all 194 COAs on file.
What is Glacier Aminos's trust grade for TB-500?
Glacier Aminos has an overall Disclosed Labs trust grade of A (96/100), computed from 194 COAs across all peptides. The most recent TB-500 COA was issued by Kovera Labs.
Where is the cheapest TB-500?
As of the latest data, Peptide Supply Co. offers TB-500 at $3.40/mg — compare with Glacier Aminos's listing at $5.90/mg. See the full TB-500 price comparison.
Is TB-500 legal to buy?
TB-500 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| TB10GA01 | — | 99.1% | Freedom Diagnostics | Endotoxin | Confirmed | View |
Disclosed Labs